<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147742</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-MA-GD-301</org_study_id>
    <nct_id>NCT03147742</nct_id>
  </id_info>
  <brief_title>An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant</brief_title>
  <official_title>An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <brief_summary>
    <textblock>
      To provide ruxolitinib through an expanded access program for the treatment of
      graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to
      participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in
      the treatment of GVHD.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Graft-versus-host Disease (GVHD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib starting dose level 10 mg orally, twice daily (BID).</description>
    <other_name>INCB018424</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female, 12 years of age or older.

          -  Have undergone an allo-HSCT from any donor source using bone marrow, peripheral blood
             stem cells, or cord blood for hematologic malignancies. Recipients of nonmyeloablative
             and myeloablative conditioning regimens are eligible.

          -  Clinically suspected all grades chronic GVHD according to NIH Consensus Criteria that
             is refractory or intolerant to corticosteroids, occurring after allo-HSCT with any
             conditioning regimen and any anti-GVHD prophylactic regimen. Clinical suspicion of
             steroid-refractory chronic GVHD by the treating physician is also sufficient.

          -  Evidence of myeloid engraftment (eg, absolute neutrophil count ≥ 1.0 × 10^9/L for 3
             consecutive days if ablative therapy was previously used). Use of growth factor
             supplementation is allowed.

          -  Evidence of platelet engraftment (ie, platelets ≥ 20 × 10^9/L).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.

          -  Be willing to avoid pregnancy or fathering children based on 1 of the following
             criteria:

               -  Women of non-childbearing potential (ie, surgically sterile with a hysterectomy
                  and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea).

               -  Woman of childbearing potential who has a negative serum pregnancy test at
                  screening and who agrees to take appropriate precautions to avoid pregnancy (with
                  at least 99% certainty) from screening through safety follow-up. Permitted
                  methods that are at least 99% effective in preventing pregnancy should be
                  communicated to the patient and their understanding confirmed.

               -  Man who agrees to take appropriate precautions to avoid fathering children (with
                  at least 99% certainty) from screening through safety follow-up. Permitted
                  methods that are at least 99% effective in preventing pregnancy should be
                  communicated to the patient and their understanding confirmed.

          -  Able to provide written informed consent and/or assent from the patient, parent, or
             guardian.

        Key Exclusion Criteria:

          -  Eligible for an existing and actively enrolling Incyte sponsored clinical trial for
             ruxolitinib for the treatment of GVHD.

          -  Clinically suspected all grades of acute GVHD as per Minnesota-Center for
             International Blood and Marrow Transplant Research (MN-CIBMTR) criteria or clinical
             suspicion of acute GVHD by the treating physician.

          -  Patients or legal guardians unable to review and sign informed consent form.

          -  Females who are pregnant or breastfeeding, and males and females who cannot comply
             with requirements to avoid fathering a child or becoming pregnant.

          -  Patients with inadequate liver function (alanine aminotransferase above 4 × upper
             limit of normal (ULN) or direct bilirubin 4 × ULN and the laboratory abnormalities are
             considered to be due to underlying liver dysfunction) unless attributed to GVHD.

          -  Patients with end stage renal function (creatinine clearance (CrCl) &lt; 15 mL/min or
             glomerular filtration rate &lt; 15 mL/min), regardless of whether hemodialysis is
             required.

          -  Any underlying or current medical or psychiatric condition that, in the opinion of the
             treating physician, would place the patient at an unacceptable risk if he or she were
             to participate in the program.

          -  Previous allergic reactions to Janus kinase (JAK) inhibitors or excipients.

          -  Patients who are currently taking any anticancer therapy (eg, chemotherapy, radiation
             therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, or tumor
             embolization).

          -  Concomitant use of any JAK inhibitor.

          -  Initiating therapy with any investigational medication.

          -  Presence of an active uncontrolled infection. An active uncontrolled infection is
             defined as hemodynamic instability attributable to sepsis or new symptoms, worsening
             physical signs, or radiographic findings attributable to infection. Persisting fever
             without signs or symptoms will not be interpreted as an active uncontrolled infection.

          -  Known HIV infection.

          -  Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment
             or at risk for HBV reactivation. At risk for HBV reactivation is defined as hepatitis
             B surface antigen positive or anti-hepatitis B core antibody positive. Previous test
             results obtained as part of standard of care before allo-HSCT that confirm a patient
             is immune and not at risk for reactivation (ie, hepatitis B surface antigen negative,
             surface antibody positive) may be used for purposes of eligibility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Naim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Cancer Transplant Institute at HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Haris Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. James Mason</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Tara Gregory</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplant Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Steven Goldstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Olga Frankfurt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. John Galvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Shaker Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Yin-Bin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5271</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Sarah Anand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. John DiPersio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Alfred Gillio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Dale Schaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Annette Fontaine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Tsiporah Shore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Miguel-Angel Perales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Betty Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Rachel Cook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Satish Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Anna Koget</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Suzanne Fanning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Research Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Vinod Parameswaran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Luis Pinerio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Michael Eckrich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Paul Carpenter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Dr. Parameswaran Hari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ruxolitinib</keyword>
  <keyword>acute or chronic steroid-refractory GVHD</keyword>
  <keyword>hematopoietic stem cell transplantation (allo-HSCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

